investor-relations

RMD

NYSE: 219.35 -13.55 -5.82% Volume: 495,489 December 5, 2022
ASX: 32.37 -1.24 -3.69% Volume: 216,363 December 6, 2022
$3.6 Billion
fiscal year 2022


15%
Adjusted EPS growth over the last five fiscal years

50%
free cash flow returned to shareholders over the last rolling five years

About ResMed

Video thumbnail

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

Featured Content

Date Download
September 8, 2021 2021 Investor Day
December 18, 2020 Corporate Citizenship Site
November 13, 2019 Software as a Service (SaaS)

Latest Reports

Date Download
October 24, 2022 1Q23 Earnings Presentation 650 KB
August 17, 2021 2021 Annual Report 1.55 MB
June 16, 2015 2021 ESG Report 15.62 MB

Email Alerts